GlassScriptPhysician profile
Pradeep Bekal
NPI 1730178633
$13,771.94
in general payments reported to CMS, 2019-2025
41 companies · $6,808 in 2025
The $6,808 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $1,733 · 2021: $1,044 · 2022: $1,370 · 2023: $793 · 2024: $1,181 · 2025: $6,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,908 · Food and Beverage: $3,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,907.50 |
| Food and Beverage | $3,874.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,736.77 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $2,352.07 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Bausch Health US, LLC | $1,710.28 | 2025 | |
| Pentax of America, INC. | $1,500.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,057.50 | 2025 | Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $662.07 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $455.24 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $426.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $335.35 | 2022-2025 | Dupixent |
| Celgene Corporation | $269.07 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $199.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $196.46 | 2019-2025 | |
| Medtronic, INC. | $191.76 | 2021-2025 | Gi Genius |
| Genzyme Corporation | $183.94 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $148.82 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $146.01 | 2020-2023 | Linzess |
| Merck Sharp & Dohme LLC | $144.32 | 2019-2022 | |
| Qol Medical, LLC | $135.54 | 2021-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $123.25 | 2019 | |
| Ferring Pharmaceuticals INC. | $116.87 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $91.99 | 2024-2025 | Omvoh |
| Amgen INC. | $78.61 | 2020-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $74.60 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $67.36 | 2025 | Voquezna |
| Celltrion USA INC. | $54.80 | 2025 | Vegzelma |
| Ethicon INC. | $53.71 | 2022 | |
| Ardelyx, INC. | $51.78 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $45.36 | 2025 | Wegovy |
| Apollo Endosurgery US INC | $43.95 | 2022 | |
| Braintree Laboratories, INC. | $28.67 | 2025 | Sutab, Suflave |
| Cook Medical LLC | $22.78 | 2024 | Hemospray |
| Shire North American Group INC | $16.22 | 2019 | |
| Ucb, INC. | $13.63 | 2019 | |
| Fresenius Kabi USA, LLC | $13.56 | 2023 | Idacio |
| Lucid Diagnostics INC. | $12.11 | 2022 | |
| Organon LLC | $11.25 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Bekal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.